Corpus ID: 11825134

Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma.

@article{Tsao1997AngiogenesisCW,
  title={Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma.},
  author={Ming-Sound Tsao and N. Liu and Trudey Nicklee and Frances A. Shepherd and Jean P. Viallet},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1997},
  volume={3 10},
  pages={
          1807-14
        }
}
  • M. Tsao, N. Liu, +2 authors J. Viallet
  • Published 1997
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
A total of 195 non-small cell lung carcinoma (NSCLC) specimens were studied for the presence of mutations in their ras family genes, for tumor vascularity, and for their immunostaining pattern with an antibody to vascular endothelial growth factor (VEGF). ras mutation was found in 37 of 104 (34.6%) adenocarcinoma specimens, in 0 of 64 squamous cell carcinomas, and in 2 of 27 (7.4%) large cell undifferentiated carcinomas. All mutations were found on the Ki-ras gene, with 37 (95%) of them on… Expand
Growth index is independent of microvessel density in non-small cell lung carcinomas.
TLDR
It is concluded that in a subset of NSCLCs, angiogenesis may be associated with VEGF, but other factors also participate in this process, with only growth partially controlled by p53 protein expression. Expand
EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN PRIMARY NON-SMALL CELL LUNG CARCINOMA
TLDR
The expression of VEGF has a significant corretation with MVD, growth, invasion, and lymph node metastasis and may be taken as the independent 9 predictors of prognosis for NSCLC. Expand
Relationship of the Kras / cmos Expression Patterns With Angiogenesis in Non-Small Cell Lung Carcinomas
Background: Neo-angiogenesis is an acquired capability vital for a tumor to grow and metastasize. Evidence has shown that the mitogen-activated protein (MAP) kinase pathway is involved in thisExpand
Relationship of the K-ras/c-mos Expression Patterns With Angiogenesis in Non-Small Cell Lung Carcinomas
TLDR
The mutually exclusive relationship between mutated K-ras and c-mos overexpression in a subset of NSCLCs implies a common signal transduction pathway in lung carcinogenesis. Expand
Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer.
TLDR
The post-operative year-survival of NSCLC was of no statistical difference between with high expression and low expression of VEGF, but in stage I case it was closed to be significant difference, it speculated that the neoangiogenesis is more obviously in early stage NSCLE but in the later stage ofNSCLC, it may be covered by more complicated molecular-biological factors such as P53 and other oncogens. Expand
Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
TLDR
Angiogenic factors are poor prognostic indicators for tumour aggressiveness and survival in NSCLC and assessments of circulating levels of VEGF and possibly bFGF may be valuable future tools for treatment planning and monitoring of treatment effect and relapse. Expand
K-ras mutations in non-small-cell lung carcinoma: a review.
TLDR
Recent findings among patients treated with adjuvant chemotherapy or epidermal growth factor receptor inhibitors highlight that K-ras might yet be an important biomarker for non-small-cell lung cancer and worthy of further research. Expand
Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras.
TLDR
It is suggested that alteration in p27 levels plays an important role in lung tumor progression and that p27 Levels may have independent prognostic significance in non-small cell lung cancer. Expand
Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma.
TLDR
The results indicate that EGFR autocrine loop activity in adenocarcinoma may have alternative signaling activities aside from the activation of ras-MAP kinase pathway. Expand
Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line.
TLDR
The direct in vivo evidence that autocrine HGF-Met signaling plays significant roles in the growth and differentiation of human lung adenocarcinoma cells is provided. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer.
TLDR
Assessment of vascular grade and PD-ECGF/TP expression should be taken into account in the design of randomized trials assessing the role of adjuvant chemotherapy in non-small-cell lung cancer. Expand
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.
TLDR
The results suggest that dominantly acting ras oncogenes may contribute to the growth of solid tumors in vivo not only by a direct effect on tumor cell proliferation but also indirectly, i.e., by facilitating tumor angiogenesis. Expand
K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.
TLDR
The presence of K-ras point mutations defines a subgroup of patients with lung adenocarcinoma in whom the prognosis is very poor and disease-free survival is not usually long despite radical resection and a small tumor load. Expand
ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.
TLDR
The findings suggest that ras gene mutations may be prognostic, especially in the early stage adenocarcinoma of the lung, where G to T transversions were most common and a history of tobacco use was not always a factor contributing to mutation. Expand
Clinical significance of ras oncogene activation in human lung cancer.
TLDR
K-ras mutations identify a subgroup of patients with adenocarcinoma of the lung who have a very poor prognosis despite radical resection of their tumor, and could be to aid in the selection of patients for specific therapeutic interventions, such as adjuvant chemotherapy. Expand
Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.
TLDR
It is concluded that mutational K-ras activation is present in about a third of adenocarcinomas of the lung and that the mutational event may be a direct result of one or more carcinogenic ingredients of tobacco smoke. Expand
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.
TLDR
The number of microvessels per 200x field in the areas of most intensive neovascularization in an invasive breast carcinoma may be an independent predictor of metastatic disease either in axillary lymph nodes or at distant sites (or both). Expand
Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines.
TLDR
Ras mutations play a role in the pathogenesis of a subset of NSCLC but are not involved in SCLC, and G to T or A to T transversions were the most common base substitutions occurring in codons 12 and 61 respectively. Expand
Proto-oncogene and growth factor/receptor expression in the establishment of primary human non-small cell lung carcinoma cell lines.
  • C. Liu, M. Tsao
  • Biology, Medicine
  • The American journal of pathology
  • 1993
TLDR
The results suggest that autocrine growth loops play important roles in the ability of NSCLC cells to proliferate continuously in monolayer culture and that most cell lines can be established only from poorly differentiated carcinomas. Expand
Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.
TLDR
K-ras point mutation positive subset had poorer survival, nine of the 13 patients died during the follow-up period as compared with 22 of 53 patients with no mutation in the K-ras gene (P = 0.01), the difference was also strikingly significant when stratified according to node status. Expand
...
1
2
3
4
5
...